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Abstract
Objective To assess whether supplementation with calcium and
cholecaliferol (vitamin D3) reduces the risk of fracture in women
with one or more risk factors for fracture of the hip.
Design Pragmatic open randomised controlled trial.
Setting Practice nurse led clinics in primary care.
Participants 3314 women aged 70 and over with one or more
risk factors for hip fracture: any previous fracture, low body
weight ( < 58 kg), smoker, family history of hip fracture, or fair
or poor self reported health.
Intervention Daily oral supplementation using 1000 mg
calcium with 800 IU cholecaliferol and information leaflet on
dietary calcium intake and prevention of falls, or leaflet only
(control group).
Main outcome measures Primary outcome measure was all
clinical fractures and secondary outcome measures were
adherence to treatment, falls, and quality of life (measured with
the SF-12).
Results 69% of the women who completed the follow-up
questionnaire at 24 months were still taking supplements (55%
with inclusion of randomised participants known to be alive).
After a median follow-up of 25 months (range 18 to 42
months), clinical fracture rates were lower than expected in
both groups but did not significantly differ for all clinical
fractures (odds ratio for fracture in supplemented group 1.01,
95% confidence interval 0.71 to 1.43). The odds ratio for hip
fracture was 0.75 (0.31 to 1.78). The odds of a woman having a
fall at six and 12 months was 0.99 and 0.98, respectively. Quality
of life did not significantly differ between the groups.
Conclusion We found no evidence that calcium and vitamin D
supplementation reduces the risk of clinical fractures in women
with one or more risk factors for hip fracture.
Registration ISRCTN26118436, controlled trials registry.
Introduction
Low trauma fractures represent a major burden of illness and
cost to society.1–3 This burden is likely to increase with ageing
populations and because the age specific incidence of hip
fracture seems to be increasing.4 Effective strategies are needed
in a community setting to prevent the continuing rise in hip and
other fractures and to reduce the associated excess morbidity
and cost.
One relatively inexpensive method of reducing fracture rates
might be supplementation with calcium and vitamin D. A
randomised trial among female residents of French nursing
homes showed significant reductions in both hip and non-hip
fractures among those assigned supplementation with calcium
and cholecaliferol (vitamin D3),
5 and a study among community
dwelling American men and women also noted a reduction in
non-vertebral fractures in women receiving supplementation.6
More recently another study among women in French nursing
homes noted a large but statistically non-significant reduction in
hip, but not non-hip, fractures among those assigned calcium
and vitamin D supplementation.7 The only trial that had fracture
as the main end point was the original French nursing home
study. It remains unknown whether these results can be general-
ised to populations outside of institutional care settings in
France. Supplementation with calcium and vitamin D might be
expected to prevent fractures not only through reductions in
bone loss but by reducing falls. A recent systematic review found
that vitamin D supplementation can reduce falls and falling by
22%.8
We assessed whether giving calcium and vitamin D
supplements to community dwelling older women at increased
risk of hip fracture would reduce their risk of any fracture.
Participants and methods
We identified women aged 70 and over who had at least one self
reported risk factor for hip fracture: low bodyweight ( < 58 kg),
any previous fracture, maternal history of hip fracture, smoker,
and poor or fair health. These risk factors were taken from a
large population study in the United States9: we subsequently
confirmed in a British cohort study that, apart from smoking,
these risk factors predict the risk of hip and non-hip fractures.10
We assessed self reported calcium consumption through a brief
10 item questionnaire that was sent to the women along with
questions on risk factors for fracture.
Women were excluded from the study if they could not give
written consent or were receiving any calcium supplementation
of more than 500 mg a day. We also excluded women with a his-
tory of kidney or bladder stones, renal failure, or hypercalcaemia.
Details of previous trials are on bmj.com
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Recruitment and randomisation
After a pilot study in the York area in September 1999, we began
recruitment for the main trial in September 2001.We asked gen-
eral practices across England to post information about the
study, a consent form, and a questionnaire on risk factors for
fracture to all women aged 70 and over. Women with cognitive
impairment or a life expectancy of less than six months were to
be excluded. Eligible women were asked to return the completed
questionnaire to the relevant trial coordinating centres
(Hertfordshire, Newcastle, or York).
Eligible women were randomised (stratified by practice) by
computer at the York Trials Unit by an independent person with
no knowledge of the participants’ characteristics. We initially
randomised in favour of the control group in a 2:1 ratio as this
was hypothesised to be the most efficient allocation ratio given
the study resources.11 We included research related costs (for
example, extra staff), not the costs of the supplements, in the esti-
mation only. Although a 2:1 ratio in favour of one arm may be
considered extreme, the effect is minimal in terms of statistical
power—for example, for a fixed sample size the power would be
reduced from 80% to 75%.We increased our sample size to com-
pensate for this reduction. A reanalysis of the trial’s cost profile
once recruitment had started showed that the optimum
allocation ratio was 3:2. Towards the end of the study we
therefore changed the allocation to 1:1.
Intervention and control groups
Before supplementation was started we sought written
confirmation from the doctors that the participants had no
known contraindications. Participants were also invited to see a
nurse at their practice, who discussed the study and also checked
for contraindications. Women who after randomisation were
identified as having contraindications to calcium and vitamin D
supplements were excluded from supplementation but were
retained for follow-up and analysis on an intention to treat basis.
The nurses gave participants general lifestyle advice on how to
reduce their risk of fracture and six months supply of 1000 mg of
calcium (calcium carbonate) and 800 IU of cholecalciferol (vita-
min D3) as two tablets daily (Calcichew D3 Forte; Shire,
Hampshire). Participants were recalled to see the practice nurse
after six months and given a further supply of supplements if
they wanted to continue with the study.
The control group were sent a leaflet with general advice on
prevention of falls and on how to consume adequate calcium
and vitamin D from dietary sources. The intervention group also
received this leaflet.
Outcomes
The main outcome was fracture, excluding those of the digits, rib,
face, and skull. Secondary outcomes included hip fracture; qual-
ity of life—as measured by the 12 item short form health survey
questionnaire (SF-12)12 and the European quality of life
instrument (EuroQol); death; visits to the doctor and hospital
admissions; falls and fear of falling. Falls were self reported over
the previous six months, and fear of falling was measured on a
simple six point Likert scale.
Outcome data were mainly collected from questionnaires
posted to participants every six months. Doctors were asked to
confirm fractures in those women who reported a fracture in the
previous six months. Information on fractures was also collected
from the doctors of non-responders to the final questionnaire.
For the principal analysis we included only confirmed fractures.
Adherence was measured through self report every six months.
We chose to report quality of life data at six and 12 months
because of the reduction in follow-up rates with time for the
quality of life questionnaires.
Sample size and statistical analysis
From previous work, and given a median follow-up period of 24
months, we presumed an all fracture rate of 10% among
untreated participants.13 When two studies on calcium and
vitamin D were combined in a random effects meta-analysis, the
pooled reduction of fracture was 34%.5 6 We determined that to
observe such a reduction in our population with 80% power
(P = 0.05; two tailed) we would require 2855 participants to be
allocated in a 2:1 ratio, allowing for a 20% dropout rate.
All participants were included in the analysis on an intention
to treat basis. For our main analysis we used survival analysis to
compare time to first fracture between the groups. We also
undertook a logistic regression analysis adjusting for practice.
We undertook subgroup analyses to compare rates for hip and
wrist fracture between the two groups and secondary analyses
with all reported fractures whether or not these had been
confirmed. If a woman had more than one fracture we included
only the first fracture in the analysis. We adjusted for practice
because we changed the allocation ratio during the trial. In our
unadjusted analysis we present the incidence of fracture by
equally or unequally allocated groups as in any meta-analysis
these need to be entered as two separate studies.
Pilot study
Between December 2000 and August 2001 we undertook a pilot
trial at the York Centre to estimate recruitment rates. The 117
General practices (n=107)
Women invited (n=48 987)
Women responding (n=11 022)
Control group (n=1993) Intervention group (n=1321)
Women randomised (n=3454)
Women excluded:
 Not meeting inclusion criteria (n=3078)
 Refused to participate (n=4490)
No seen and given supplements
(n=1211)
Adherence at six months
(735/1199; 61.3%)
Supplement use at six months
(107/1982; 5.4%)
Adherence at 12 months
(745/1185; 62.9%)
Supplement use at 12 months
(129/1975; 6.5%)
Adherence at 18 months
(514/877; 58.6%)
Supplement use at 18 months
(111/1961; 5.7%)
≥1 fractures (n=58)
No fractures (n=1211)
Died (n=57)
Missing (n=48)
Withdrawn (n=4)
≥1 fractures (n=91)
No fractures (n=1839)
Died (n=68)
Missing (n=53)
Withdrawn (n=10)
Excluded (n=140):
 Four practices withdrawn before treatment (n=128)
 One participant randomised twice
 Protocol violation (participant aged<70) (n=3)
 Died between randomisation and trial inclusion (n=8)
Fig 1 Flow of participants through trial. Adherence was estimated by
subtracting those known to have died. Those who failed to return questionnaires
were assumed not to be taking treatment
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participants recruited in this pilot are included in the main trial
report.
Results
Between September 2001 and November 2002 we recruited
3197 women in addition to the 117 participants recruited during
the pilot trial (3314 in total). The recruitment rate of 7% instead
of the presumed 5% allowed us to exceed our planned sample
size by 16%.
Overall, 48 987 women registered with 107 general practices
were invited to take part in our trial (fig 1). Of the 11 022 women
who returned the questionnaire, 3078 were ineligible and 4490
did not want to take part, leaving 3454 women (7.0% of those
originally invited). Table 1 shows the baseline characteristics of
the participants. The intervention and contol groups were well
balanced across all important predictors of fracture.
Over a median follow-up of 25 months, 149 confirmed frac-
tures were reported, lower than anticipated. Time to fracture did
not differ between the groups (fig 2) and we found no evidence
of a benefit of supplementation in the prevention of fractures
(table 2). When we took into account all reported fractures
(including those not confirmed by a doctor) the results were not
changed (adjusted odds ratio 1.60, 95% confidence interval 0.75
to 3.40).
We also examined the risk of falls, falling, and quality of life.
We found no evidence of an effect on falls. After adjusting for
practice, the odds ratio of a woman having a fall at six months
was 0.99 (0.81 to 1.20). At 12 months we found no evidence that
supplementation reduced falling (0.98, 0.79 to 1.20). We also
found no differences in quality of life (table 3).
Adherence
Rates for adherence at 12 months were about 63% when we
included all women randomised but excluded those who had
died.We compared women taking supplements with those in the
control group to determine whether women who adhered to
treatment might have had a reduced fracture rate. We found no
evidence of any benefit (1.03, 0.68 to 1.56).
Discussion
We found no evidence that supplementation with calcium and
cholecalciferol (vitamin D3) affects fracture rates over two years in
Table 1 Baseline characteristics of women receiving calcium and cholecalciferol (vitamin D3) supplementation (intervention group) or only advice on diet or
prevention of falls to prevent fractures. Values are percentages (numbers) unless stated otherwise
Variable Intervention group (n=1321) Control group (n=1993)
Mean (SD) age 77.0 (5.10) 76.7 (5.02)
Mean (SD) weight (kg) 64.9 (12.07) 64.9 (11.93)
Bodyweight <58 kg 32.7 (417/1277) 32.8 (629/1918)
Previous fracture (any) 58.7 (776/1321) 58.3 (1161/1990)
No fracture 10 years before randomisation 80.6 (1064/1321) 80.2 (1599/1993)
Smoker 8.6 (101/1171) 7.4 (127/1717)
Self reported poor or fair health 38.9 (510/1311) 37.1 (737/1986)
Maternal hip fracture 16.8 (222/1320) 16.1 (320/1991)
Fall in previous 12 months 33.7 (445/1320) 34.2 (681/1993)
Mean (SD) SF-12 scores*:
Mental health component 51.42 (9.75) 51.16 (9.66)
Physical component 40.14 (11.96) 40.29 (12.18)
EuroQol 0.700 (0.251) 0.694 (0.254)
Mean estimated dietary calcium intake (mg/d)† 1075 (338) 1084 (346)
*High scores denote good mental and physical health.
†Self reported.
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Fig 2 Time to first fracture in women allocated calcium and vitamin D
supplementation or only advice on diet and prevention of falls
Table 2 Odds of fracture in women receiving calcium and cholecalciferol (vitamin D3) supplementation (intervention group) and those receiving only advice
on diet and prevention of falls. Values are percentages (numbers) unless stated otherwise
Confirmed fractures Intervention group (n=1321) Control group (n=1993) Adjusted odds ratio (95% CI)* P value
All fractures:
Unequally allocated group† 4.8 (34/714) 5.0 (69/1391) 1.01 (0.71 to 1.43) 0.97
Equally allocated group 4.0 (24/607) 3.7 (22/602)
Hip fractures:
Unequally allocated group 0.4 (3/714) 1.1 (15/1391) 0.75 (0.31 to 1.78) 0.51
Equally allocated group 0.8 (5/607) 0.3 (2/602)
Hip and wrist fractures:
Unequally allocated group 2.4 (17/714) 3.2 (44/1391) 0.89 (0.56 to 1.44) 0.64
Equally allocated group 2.0 (12/607) 1.5 (9/602)
*Adjusted for practice.
†Two women randomised to control group for every one allocated to treatment group.
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women aged 70 or over with one or more risk factors for fracture
of the hip.
Combined calcium and cholecaliferol
Five trials have been published on combined calcium and
vitamin D (see bmj.com). Two were in French nursing homes.5 7
Our population was recruited from the community. A
community study in Denmark showed a modest (16%),
statistically significant, reduction in fractures.14 This study was a
2×2 factorial trial, however, which did not take clustering into
account in the analysis despite the participants being
randomised by cluster. With only one cluster in each cell, this
resulted in two clusters receiving calcium and vitamin D and
cluster replication may have been insufficient to control for con-
founding at the level of the cluster.15 Another community based
trial in the United States studied bone density and although it
showed a significant benefit on fractures, this study was relatively
small.6 The latest calcium and vitamin D study to be published is
the Medical Research Council RECORD trial,16 which is a
secondary prevention study in hospital based fracture clinics in
the United Kingdom. This study essentially showed the same
findings as our trial, that there was no evidence of a benefit from
calcium or vitamin D supplementation either alone or in combi-
nation in preventing fractures.
Our study differs from the two French studies,5 7 which
showed a large benefit from supplementation on hip fractures, in
that our population was generally more healthy and living inde-
pendently in the community. People living in sheltered
accommodation or nursing homes may be at more risk of a low
calcium and vitamin D intake and at higher risk of fracture. Also
because our study was undertaken among women living
independently in the community who could give consent, our
results do not apply to men, those in residential care, or those
with dementia. Patients in residential care or with dementia are
of particular interest clinically because they have a higher risk of
fracture.
Vitamin D alone
Four large randomised studies looked at vitamin D supplemen-
tation (see bmj.com). Lips et al observed a non-significant
increase in the hazard of hip fractures in 2578 older Dutch men
and women in primary care receiving a daily dose of 400 IU vita-
min D.17 A more recent primary care trial of an annual injection
of 300 000 IU of vitamin D among 9440 men and women from
southern England reported a small non-significant increase in
all fractures with a large, borderline statistically significant
increase in hip fractures.18 In contrast, a trial of high dose oral
vitamin D (100 000 units) every four months among 2686
mainly retired male doctors showed a borderline statistically sig-
nificant 22% reduction in all osteoporotic fractures.19 The
RECORD trial also studied vitamin D alone and found no
evidence of benefit in preventing fractures (see bmj.com). Our
study differed from these four in that we included only women
and selected them on the basis of risk factors for fracture,
whereas these studies included men and may have sampled a
population at lower risk. Nevertheless, putting our study into the
context of these four large trials, with only one showing a signifi-
cant benefit, suggests that overall vitamin D supplementation
among a general primary care population may not be an effec-
tive intervention for reducing fractures. A recent Norwegian
study, using a quasirandom method of allocation (alternation) of
vitamin D supplements in cod liver oil among 1144 nursing
home residents, found a slight, non-significant increase in hip
fractures and a slight, non-significant decrease in all fractures
(relative risk 1.09, 95% confidence interval 0.73 to 1.63 and 0.92,
0.66 to 1.27, respectively).20
Falls
We found no evidence that vitamin D supplementation reduced
the incidence of falls, as previously hypothesised.8
Strengths and weaknesses of the study
Our study was large and targeted women at high risk of fracture.
We chose to use a pragmatic design, which allows our results to
be generalised to a usual care setting. We did not, however, use a
placebo preparation in the control group and this could have
biased the results in several ways. Firstly, dilution effects could
have occurred if significant numbers of control participants had
started calcium and vitamin D. This was not a problem, however,
as by 18 months this applied to fewer than 6% of the
participants, with about 3% being prescribed supplementation
by their doctor. Secondly, differential reporting of fracture
Table 3 Secondary outcomes in women receiving calcium and cholecalciferol (vitamin D3) supplementation (intervention group) and those receiving only
advice on diet and prevention of falls. Values are percentages (numbers) unless stated otherwise
Secondary outcome measures Intervention group (n=1321) Control group (n=1993) Adjusted odds ratio* (95% CI)
Adjusted mean difference*
(95% CI) P value
Deaths:
Unequally allocated group† 3.8 (27/714) 3.7 (51/1391) 1.26 (0.87 to 1.83) — 0.22
Equally allocated group 4.9 (30/607) 2.8 (17/602)
≥1 hospital admissions in first 12
months:
Unequally allocated group 41.7 (220/528) 42.8 (481/1124) 0.86 (0.72 to 1.03) — 0.10
Equally allocated group 38.2 (126/330) 46.7 (189/405)
≥1 visits to doctor in first 12
months:
Unequally allocated group 80.4 (430/535) 80.5 (917/1139) 0.84 (0.67 to 1.04) — 0.11
Equally allocated group 76.5 (251/328) 82.8 (346/418)
SF-12 (SD) scores at 12 months
Physical component:
Unequally allocated group 41.66 (11.74) 41.20 (11.92) — −0.152 (−0.10 to 0.7) —
Equally allocated group 41.33 (11.38) 39.68 (12.05)
Mental health component:
Unequally allocated group 52.02 (9.17) 51.87 (9.23) — 0.03 (−0.04 to 0.97) —
Equally allocated group 51.73 (9.23) 50.77 (10.00)
*Adjusted for practice and age.
†Two women randomised to control group for every one allocated to treatment group.
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outcomes could have occurred. We therefore confirmed all frac-
tures with the participants’ doctors and we ascertained fracture
status from the doctors of non-responders to the questionnaires.
Self reports of fracture have been shown to be reliable.21 There-
fore, lack of a placebo control was not, in our view, a problem.
Fewer fractures occurred than we anticipated in our popula-
tion, thus reducing the power of our study to observe modest dif-
ferences between groups. This was, however, offset to some
degree by us exceeding our planned sample size. Furthermore, a
trial published subsequent to the start of our study noted little
effect of supplementation on all fractures7 (our main end point).
Including this result in a meta-analysis would have reduced the
difference in fracture rates we might have expected to find.
Therefore, our study was underpowered so that we could not
reliably exclude a reduction in all fractures of less than 30%. Fur-
thermore, adherence rates were only a little more than 60% at 12
months. This may have attenuated any effect of treatment. As this
was a pragmatic trial this will be the level of adherence seen rou-
tinely in general practice.
Although we found no evidence of a benefit on fractures in
older community dwelling women given calcium and vitamin D
supplementation, we cannot exclude a clinically significant ben-
efit of supplementation owing to the relatively wide confidence
intervals around our estimate of effect.
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